Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
Portfolio Pulse from Benzinga Newsdesk
Recursion (NASDAQ:RXRX), a clinical stage TechBio company, has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of assessing the safety, tolerability and pharmacokinetic profile of REC-3964, with no serious adverse events reported.
September 05, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Recursion's successful completion of the Phase 1 study for REC-3964 indicates positive progress in their drug discovery process. This could potentially boost investor confidence in the short term.
The successful completion of a Phase 1 study is a significant milestone in the drug development process. This news indicates that Recursion's REC-3964 has passed initial safety and tolerability checks, which is a positive sign for the company's drug discovery process. This could potentially boost investor confidence and have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100